Numinus Wellness (NUMI.T) gets Health Canada approval for ayahuasca

Numinus Wellness (NUMI.T) got the Health Canada nod to study ayahuasca and San Pedro at its research facility, Numinus Bioscience today.

The license expansion works to boost NUMI’s profile as a recognized global research centre for psychedelics and supplements the existing work on psilocybe species and other compounds.

“There is little industry research currently being done on these botanicals. This exciting advancement at Numinus broadens our study of naturally occurring ethnobotanical substances and admixtures and the synergies of the compounds. This is a first step in helping us better understand their mechanisms and potential therapeutic applications,” said Sharan Sidhu, science officer and general manager of Numinus Biosciences.

The renewal of its dealer’s license gives Numinus the permission required to work with San Pedro cactus, the beta-carbolines harmaline and harmalol, and a number of other botanical materials. Most of these have been used in indigenous traditional practices. Harmaline and harmalol are naturally occurring psychoactive chemicals that happen in the B. Caapi cactus, while P. Viridis, D. Cabrerana and M. Tenuiflora, which are the chemicals respectively Numinus can work with, contain DMT.

Here’s a short video wherein CEO Payton Nyquvest discusses what’s coming for psychedelics.

 

Numinus received prior approvals, extending the license to include DMT, ketamine, LSD, MDMA, mescaline, psilocin and psilocybin. They can hold, test, produce, assemble, sell, export and deliver these chemicals.

“Many naturally occurring psychedelic compounds have already been in traditional use for millennia. These amendments honour and build on those practices while allowing us to do novel clinical research and deepen the body of scientific data for scaled development and greater public access to much-needed therapies,” said Payton Nyquvest, chief executive officer and founder, Numinus.

Let’s see how the designation for ayahuasca altered their fortunes.

ayahuasca

Source: stockwatch.com

NUMI is down $0.02 today and trading at $0.49 today.

–Joseph Morton

The post Numinus Wellness (NUMI.T) gets Health Canada approval for ayahuasca appeared first on Equity.Guru.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.